Nuclear Medicine

Nuclear medicine (also called molecular imaging) includes positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. Nuclear imaging is achieved by injecting small amounts of radioactive material (radiopharmaceuticals) into patients before or during their scan. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

RSS icon
Recall

FDA issues Class I recall notice for Philips nuclear imaging system

The alert pertains to its BrightView SPECT family of products, with concerns a loose screw could cause machinery to fall on a patient. 

February 6, 2024
brain money alzheimer dementia

Biogen discontinues Alzheimer’s drug Aduhelm, once expected to spur surge in imaging use

Screening for the drug necessitated a PET scan, and individuals also required a baseline MRI within one year before treatment, with more to follow. 

February 2, 2024

Manufacturers partner to develop radioisotopes used in cancer drugs, clinical trials

Eckert & Ziegler and Nucleus RadioPharma have signed an agreement to address the increasing demand for Lu-177 and Ac-225.

January 31, 2024
supply_chain.jpg

ITM to supply Alpha-9 radioisotopes to develop new cancer drugs

The German manufacturer and Canadian drug developer are partnering to address the supply crunch of radioisotopes.

January 30, 2024

Hospital to decommission its nuclear medicine department due to lack of use

“We’re getting less and less referrals, and that number is dropping,” Anthony Mitarotondo, MD, director of Stony Brook Radiology, said during a recent public hearing. 

January 25, 2024
Lab Research

Isotope used in cancer drug development shipped for clinical trials

Actinium-225 remains in short supply, slowing drug research.

January 24, 2024
Jamie Bourque, MD, medical director of the nuclear cardiology and stress laboratory, and medical director of the echocardiography lab, at the University of Virginia, discusses a new multimodality consensus statement for imaging cardiac amyloidosis. This area has rapidly expanded over the past couple years now that there are drugs to treat the condition. Examples of nuclear imaging for cardiac amyloidosis.

New ASNC quality metrics will support standardization of imaging for cardiac amyloidosis

Interest in cardiac amyloidosis has been on the rise in recent years. Jamie Bourque, MD, talked to Cardiovascular Business about an upcoming consensus statement focused on using cardiac imaging to evaluate patients for signs of this serious condition. 

January 18, 2024
Rob deKemp, PhD, FASNC, University of Ottawa, Canada, explains new nuclear cardiac imaging dose lowering techniques for PET and SPECT.

How to achieve much lower radiation doses in cardiac nuclear imaging

The radiation doses associated with CT have decreased significantly, leaving nuclear cardiology as the modality with the highest doses in all of cardiac imaging. Rob deKemp, PhD, talked to us about some of the many ways imagers can work to address this issue.

January 17, 2024
Displaying 25 - 32 of 259
Design by Adaptive Theme